Company Information
CIN
Status
Date of Incorporation
01 March 1990
State / ROC
Hyderabad / ROC Hyderabad
Last Balance Sheet
31 March 2022
Last Annual Meeting
30 September 2022
Paid Up Capital
757,700,000
Authorised Capital
760,000,000
Directors
Sujana Kadiam
Director/Designated Partner
over 2 years ago
over 2 years ago
Kollipara Koteswara Rao
Director/Designated Partner
over 2 years ago
over 2 years ago
Swetha Marri
Director/Designated Partner
about 5 years ago
about 5 years ago
Santhosh Kumar .
Director/Designated Partner
about 5 years ago
about 5 years ago
Past Directors
Polavarapu Vikram
Managing Director
about 6 years ago
about 6 years ago
Paradesi Naga Vaishali
Director
over 7 years ago
over 7 years ago
Shyam Shankar Das
Director
almost 11 years ago
almost 11 years ago
Puranik Sarang Subhash
Director
almost 11 years ago
almost 11 years ago
Prasanta Kumar Ghosh
Director
almost 20 years ago
almost 20 years ago
Sri Krishna Nuthalapati
Director
almost 20 years ago
almost 20 years ago
Soma Sekhar Marthi
Director
about 27 years ago
about 27 years ago
Narayana Murthy Pentyala
Director
over 29 years ago
over 29 years ago
Patents
Immunotoxins platform to prevent HIV mediated AIDS progression and other autoimmune diseases is disclosed. AIDS is characterized by a progressive decline of CD4+ immune cells in the host"s system. Existing antiretroviral drug therapies are effective in containing the viral replication and thus bring up the CD4+ T ce...
Fusion proteins for the treatment of Multiple Sclerosis and other autoimmune diseases are disclosed. Multiple sclerosis (MS) is an inflammatory demyelinating autoimmune disease of the central nervous system. MS is triggered by the body"s own immune system attacking the myelin sheath around the axons. Current medical...
Adeno-associated virus 2/8 - microRNA-101 (AAV2/8-miR-101) therapy for liver cancer is provided. In particular, the invention provides a recombinant AAV 2/8 vector, comprising mutated capsid, for the enforced expression of pre-miR-101 and for the treatment of liver cancer.
Antibody for targeted induction of Apoptosis, CDC and ADCC mediated killing of Cancer cells, TBL-CLN1, is disclosed. The antibodies, TBL-CLN1, are monoclonal antibodies which can specifically target and bind to the epitope of SEQ ID NO: 1 expressed on cancer cells which further leads to killing of cancer cells. TBL-...
Adeno-associated virus EzH2 shRNA (AAV 2-EzH2 shRNA) based treatment, incorporating targeted gene silencing of cancer metastasis promoting gene EzH2, through RNA interference (RNAi), mediated by recombinant adeno-associated virus vector, is provided. The present invention provides an efficient and safe therapeutic c...
Exemplary aspects of the present invention disclosure relates to a novel pharmaceutical formulation and a process for oral delivery of biotherapeutic peptides and proteins like insulin conjugated with biotin to form a complex and encapsulated by a polymer for binding to its own as well as biotin receptors of the gas...
A method for the production of Docosahexaenoic acid (DHA) by batch fermentation is disclosed. The production of DHA from sources such as sea food and algae are already known. However, sources such as sea food and algae have disadvantages such as uneven product quality and un-assured product safety. The production of...
A method for treating type 1 and type 2 diabetes by administering an oral pharmaceutical formulation which comprises of insulin or its analogues amalgamated with suitable encapsulating agents and pharmaceutical excipients. The encapsulated pharmaceutical oral formulation protects insulin or its analogues from harsh ...
ABSTRACT
“FORMULATION FOR NASAL DELIVERY OF INSULIN AND OTHER
PROTEINS AND PEPTIDES”
The present invention relates to a pharmaceutical preparation for nasal insulin administration in diabetic population comprising a polypeptide hormone insulin, or an analogue thereof, and a quaternised and thiolated Chitosan ...
The present invention is in the field of oncolytic viruses. The invention provides new poxviruses which are engineered to be defective for the function encoded by the M2L locus (ie, m2 function). Such poxviruses lack a functional m2 binding activity to at least one or both of CD80 and CD86 co-stimulatory antigens. S...
Registered Trademarks
[Class : 5] Pharmaceutical, Veterinary And Sanitary Preparations; Dietetic Substances Adapted For Medical Use, Food For Babies; Plasters, Materials For Dressings; Materials For Stopping Teeth, Dental Wax; Disinfectants; Preparation For Destroying Vermin; Fungicides, Herbicides
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
[Class : 1] Chemicals Used In Industry And Science[Class : 5] Pharmaceutical And Veterinary Preparations[Class : 42] Scientific And Technological Services And
Research Issued By Engineers
[Class : 5] Pharmaceuticals Preparations For Use In Immunotherapy.
Trade mark is likely to be removed due to non filing of Renewal request within prescribed time limit In case of any discripancy contact respective TM Registry.
Charges
08 April 2010
Department Of Biotechnology
5 Crore
30 July 2008
Ge Capital Services India
8 Lak
23 May 2007
Union Bank Of India
3 Crore
30 May 2005
The Karur Vysya Bank Ltd.
59 Lak
20 October 1996
Ankot Tradesec Ltd.
70 Lak
17 June 1993
State Bank Of India
30 Lak
10 July 1992
Industrial Development Bank Of India
1 Crore
14 January 1992
Industrial Development Bank Of India
3 Crore
10 July 1992
Industrial Development Bank Of India
0
20 October 1996
Ankot Tradesec Ltd.
0
30 July 2008
Ge Capital Services India
0
08 April 2010
Department Of Biotechnology
0
14 January 1992
Industrial Development Bank Of India
0
17 June 1993
State Bank Of India
0
30 May 2005
The Karur Vysya Bank Ltd.
0
23 May 2007
Union Bank Of India
0
10 July 1992
Industrial Development Bank Of India
0
20 October 1996
Ankot Tradesec Ltd.
0
30 July 2008
Ge Capital Services India
0
08 April 2010
Department Of Biotechnology
0
14 January 1992
Industrial Development Bank Of India
0
17 June 1993
State Bank Of India
0
30 May 2005
The Karur Vysya Bank Ltd.
0
23 May 2007
Union Bank Of India
0
10 July 1992
Industrial Development Bank Of India
0
20 October 1996
Ankot Tradesec Ltd.
0
30 July 2008
Ge Capital Services India
0
08 April 2010
Department Of Biotechnology
0
14 January 1992
Industrial Development Bank Of India
0
17 June 1993
State Bank Of India
0
30 May 2005
The Karur Vysya Bank Ltd.
0
23 May 2007
Union Bank Of India
0
10 July 1992
Industrial Development Bank Of India
0
20 October 1996
Ankot Tradesec Ltd.
0
30 July 2008
Ge Capital Services India
0
08 April 2010
Department Of Biotechnology
0
14 January 1992
Industrial Development Bank Of India
0
17 June 1993
State Bank Of India
0
30 May 2005
The Karur Vysya Bank Ltd.
0
23 May 2007
Union Bank Of India
0
Documents
Form MGT-7-19122020_signed
List of share holders, debenture holders;-18122020
Copy of MGT-8-18122020
Form INC-22-17112020_signed
Proof of Registered Office address(Conveyance/Lease deed/Rent Agreement along with the rent receipts) etc-17112020
Copies of the utility bills as mentioned above (not older than two months)-17112020
XBRL financial statements duly authenticated as per section 134 (including Board's report,auditor's report and other documents)-17112020
XBRL document in respect Consolidated financial statement-17112020
Optional Attachment-(1)-17112020
Form AOC-4(XBRL)-17112020_signed
Form ADT-1-27102020_signed
Copy of written consent given by auditor-27102020
Copy of resolution passed by the company-27102020
Copy of the intimation sent by company-27102020
Form MGT-14-08102020_signed
Form DIR-12-08102020_signed
Optional Attachment-(1)-07102020
Copy(s) of resolution(s) along with copy of explanatory statement under section 173-07102020
Optional Attachment-(1)-06102020
Form MGT-15-05102020_signed
Form DPT-3-11092020-signed
Optional Attachment-(4)-10062020
Optional Attachment-(2)-10062020
Declaration of the appointee director, Managing director, in Form No. DIR-2;-10062020
Optional Attachment-(1)-10062020
Form DIR-12-10062020_signed
Optional Attachment-(3)-10062020
Notice of resignation;-22052020
Evidence of cessation;-22052020
Optional Attachment-(2)-22052020
